Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
304 GBX | +4.83% | +10.14% | +7.42% |
Apr. 26 | EU Panel Backs Approval of Takeda’s Colorectal Cancer Drug | MT |
Apr. 26 | Hutchmed notes CHMP's positive opinion for fruiquintinib approval | AN |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+7.42% | 3.08B | |
+26.47% | 661B | |
+26.74% | 566B | |
-6.33% | 352B | |
+19.35% | 332B | |
+4.23% | 283B | |
+13.43% | 231B | |
+4.71% | 200B | |
-9.53% | 195B | |
-4.04% | 145B |
- Stock Market
- Equities
- HCM Stock
- News HUTCHMED (China) Limited
- HUTCHMED's Metastatic Colorectal Cancer, Neuroendocrine Tumors Drugs to Remain on China's National Reimbursement Drug List